Driving First‑Cycle ANDA Approvals Through Strategic Regulatory Planning
Abstract
Getting first-cycle approval for Abbreviated New Drug Applications (ANDAs) is crucial for generic drug sponsors, especially when quick market entry and regulatory risks are at stake. Even though the U.S. Food and Drug Administration has established clear review processes and goals under the Generic Drug User Fee Amendments (GDUFA), many ANDAs remain delayed by avoidable problems in bioequivalence, chemistry, manufacturing, and controls, labeling, and facility compliance.
This article looks at what affects first-cycle ANDA approval. It highlights the importance of making early regulatory decisions, spotting risks before filing, and keeping the team on the same page. It also covers how to prepare before and after submission, maintain quality, answer review questions, and get ready for inspections.
The article uses performance metrics and real-world examples to show how sponsors can shorten review times and improve their chances of approval. Careful planning and steady execution help organizations avoid last-minute changes and achieve more predictable, timely approvals.
Conclusion: A structured, proactive regulatory strategy significantly increases the likelihood of first-cycle ANDA approval. Early risk identification, robust submission quality, and strong cross-functional coordination help reduce review cycles and enable more predictable and timely approvals.
Downloads
References
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2023-monthly-performance
2. U.S. Food and Drug Administration. ANDA Program Statistics Overview [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from:
https://www.fda.gov/media/183116/download
3. U.S. Food and Drug Administration. Generic Drugs Program Activities Report FY 2024 [Internet]. Silver Spring (MD): FDA; 2026 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2024-monthly-performance
4. Chazin H, Woo J, Han J, et al. FDA’s generic drug program: decreasing time to approval and number of review cycles. Ther Innov Regul Sci [Internet]. 2020 [cited 2026 May 21];54:758–763. Available from:
doi: 10.1007/s43441-019-00016-2
5. Indian Pharmaceutical Alliance. Focus on First Cycle Approval of ANDAs: Regulatory Best Practices [Internet]. 2021 [cited 2026 May 21]. Available from:
https://www.ipa-india.org/sites/default/files/2025-07/Regulatory-Best-Practices-First-Cycle-ANDA-Approvals.pdf
6. U.S. Food and Drug Administration. Generic Drugs Program Activities Report FY 2025 [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/generic-drugs-program-activities-report-fy-2025-monthly-performance
7. Pawar J, Hegde N, Sharma S. Focusing on first-cycle approval in ANDA submission: understanding common deficiencies and case study insights. Ther Innov Regul Sci [Internet]. 2025 [cited 2026 May 21];59:426–437. Available from: doi: 10.1007/s43441-025-00755-5
8. Kozak D. Analysis of ANDA major bioequivalence deficiencies and approval cycle trends [Internet]. Paper presented at: GRx+Biosims; 2024 Oct 21 [cited 2026 May 21]. Available from:
https://accessiblemeds.org/wp-content/uploads/2024/12/GRxBiosims-2024-PPT-Darby-Kozak.pdf
9. U.S. Food and Drug Administration. GDUFA Performance Reports (GDUFA I–III) [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from:
https://www.fda.gov/about-fda/user-fee-performance-reports/gdufa-performance-reports
10. Jiao K, Gupta R, Fox E, et al. Characteristics of recent generic drug approvals by the US Food and Drug Administration. JAMA Netw Open [Internet]. 2019 [cited 2026 May 21];2(10):e1913029. Available from: doi: 10.1001/jamanetworkopen.2019.13029
11. U.S. Food and Drug Administration. ANDA Review Process [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/generic-drugs/anda-review-process
12. U.S. Food and Drug Administration. Office of Generic Drugs Annual Report [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/generic-drugs/annual-reports
13. U.S. Government Accountability Office. Generic Drug Applications: FDA Should Take Additional Steps to Address Factors That May Affect Approval Rates in the First Review Cycle [Internet]. GAO-19-565; 2019 [cited 2026 May 21]. Available from:
https://www.gao.gov/products/gao-19-565
14. Lionberger RA, Lee SL, et al. Quality by design concepts for ANDAs. AAPS J [Internet]. 2008 [cited 2026 May 21];10(2):268–276. Available from:
doi:10.1208/s12248 008 9026 7
15. Kulkarni SB, Gaikwad VL. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the FDA. J Pharmacol Toxicol Methods [Internet]. 2023 [cited 2026 May 21];123:107295. Available from:
doi:10.1016/j.vascn.2023.107295
16. U.S. Food and Drug Administration. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/media/87219/download
17. U.S. Food and Drug Administration. ANDA Submissions: Refuse to Receive Standards [Internet]. Silver Spring (MD): FDA; 2022 [cited 2026 May 21]. Available from:
https://www.fda.gov/media/86660/download
18. U.S. Food and Drug Administration. Form 483 Inspection Observations Data [Internet]. Silver Spring (MD): FDA; 2021 [cited 2026 May 21]. Available from:
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/inspection-observations
19. U.S. Food and Drug Administration. Drug Master Files [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/forms-submission-requirements/drug-master-files-dmfs
20. U.S. Food and Drug Administration. Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA [Internet]. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-drug-master-files-advance-certain-anda-submissions-under-gdufa
21. Gupta A, Sharma AK. A study of submissions of abbreviated new drug applications [Internet]. 2024 [cited 2026 May 21]. Available from:
https://www.ijarst.in/public/uploads/paper/650701714115121.pdf
22. U.S. Food and Drug Administration. Issuance of Information Requests and Discipline Review Letters for ANDAs [Internet]. MAPP 5220.5. Silver Spring (MD): FDA; 2024 [cited 2026 May 21]. Available from:
https://www.fda.gov/media/109649/download
23. U.S. Food and Drug Administration. Good ANDA Submission Practices [Internet]. Silver Spring (MD): FDA; 2022 [cited 2026 May 21]. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-anda-submission-practices-guidance-industry
24. U.S. Food and Drug Administration. Labeling for Human Prescription Drug and Biological Products [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/laws-acts-and-rules/fdas-labeling-resources-human-prescription-drugs
25. U.S. Food and Drug Administration. Hatch-Waxman Letters [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-letters
26. Chan C. Best practices for generic drug labeling [Internet]. Silver Spring (MD): FDA; 2025 [cited 2026 May 21]. Available from:
https://www.fda.gov/media/187302/download2
27. U.S. Food and Drug Administration. The FDA’s role in regulating and approving drugs [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/information-consumers-and-patients-drugs/overview-our-role-regulating-and-approving-drugs-video-series
28. U.S. Food and Drug Administration. Data Integrity and Compliance With Drug CGMP [Internet]. Silver Spring (MD): FDA; 2018 [cited 2026 May 21]. Available from:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/data-integrity-and-compliance-drug-cgmp-questions-and-answers
29. U.S. Food and Drug Administration. Advancing Model-Informed Drug Development Program [Internet]. Silver Spring (MD): FDA; 2023 [cited 2026 May 21]. Available from:
https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program
30. Modi P, Patel K, Modasiya J. Comparative pathways: reliance and convergence for medicines and medical devices. Int J Med Sci [Internet]. 2026 [cited 2026 May 21]. Available from: doi:10.34218/ijms_04_01_002
31. Modi P, et al. Comparability protocols as a strategic tool for postapproval CMC changes [Internet]. RAPS J Regul Aff. 2026 [cited 2026 May 21]. Available from:
https://www.raps.org/resource/comparability-protocols-as-a-strategic-tool-for-postapproval-cmc-changes.html
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
